Aptabio Therapeutics Stock Return On Equity
| 293780 Stock | 6,630 570.00 7.92% |
AptaBio Therapeutics fundamentals help investors to digest information that contributes to AptaBio Therapeutics' financial success or failures. It also enables traders to predict the movement of AptaBio Stock. The fundamental analysis module provides a way to measure AptaBio Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AptaBio Therapeutics stock.
AptaBio |
AptaBio Therapeutics Company Return On Equity Analysis
AptaBio Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current AptaBio Therapeutics Return On Equity | -17.47 |
Most of AptaBio Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AptaBio Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, AptaBio Therapeutics has a Return On Equity of -17.4655. This is much lower than that of the sector and significantly lower than that of the Biotechnology & Medical Research industry. The return on equity for all Republic of Korea stocks is notably higher than that of the company.
AptaBio Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AptaBio Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AptaBio Therapeutics could also be used in its relative valuation, which is a method of valuing AptaBio Therapeutics by comparing valuation metrics of similar companies.AptaBio Therapeutics is currently under evaluation in return on equity category among its peers.
AptaBio Fundamentals
| Return On Equity | -17.47 | |||
| Return On Asset | -0.0568 | |||
| Operating Margin | (17.13) % | |||
| Current Valuation | 794.49 B | |||
| Shares Outstanding | 10.88 M | |||
| Shares Owned By Insiders | 34.04 % | |||
| Shares Owned By Institutions | 3.46 % | |||
| Price To Sales | 926.14 X | |||
| Revenue | 223.68 M | |||
| Gross Profit | 336.97 M | |||
| EBITDA | (6.58 B) | |||
| Net Income | (10.69 B) | |||
| Cash And Equivalents | 6.57 B | |||
| Total Debt | 46.77 M | |||
| Cash Flow From Operations | (8.9 B) | |||
| Beta | 2.39 | |||
| Market Capitalization | 111.21 B | |||
| Total Asset | 64.91 B | |||
| Net Asset | 64.91 B |
About AptaBio Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AptaBio Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AptaBio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AptaBio Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in AptaBio Stock
AptaBio Therapeutics financial ratios help investors to determine whether AptaBio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AptaBio with respect to the benefits of owning AptaBio Therapeutics security.